<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00986960</url>
  </required_header>
  <id_info>
    <org_study_id>NDA 08-372</org_study_id>
    <secondary_id>NDA 08-372</secondary_id>
    <nct_id>NCT00986960</nct_id>
  </id_info>
  <brief_title>Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)</brief_title>
  <acronym>ACTH</acronym>
  <official_title>Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the use of ACTH in addition to Avonex is&#xD;
      effective in the treatment of relapsing remitting multiple sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system&#xD;
      (CNS). It is a complex, multi-factorial disease that includes inflammatory and&#xD;
      neurodegenerative processes manifesting both focally in the form of lesions and diffusely in&#xD;
      otherwise normal-appearing brain tissue. Recent data shows that ACTH can have beneficial&#xD;
      effects on specific neurodegenerative diseases and it may have superior neuroprotective&#xD;
      effects. Adding a regimen of ACTH to standard Avonex treatment may provide neuroprotection&#xD;
      and promote remyelination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Difficult to recruit due to protocol requirements - participant burden.&#xD;
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define the effect of add-on pulsed IM ACTH vs. placebo to IFNβ-1a I.M. on a voxel-wise MTR dynamic mapping of the lesions and NABT in patients with RRMS</measure>
    <time_frame>1 year</time_frame>
    <description>Effect of ACTH in MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To define the effect of add-on pulsed IM ACTH vs. placebo to IFNβ-1a I.M. in RRMS on anterior optic pathway pathology, as measured by OCT and LCLA in patients with RRMS.</measure>
    <time_frame>1 year</time_frame>
    <description>Effect of ACTH on optic health</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Adrenocorticotropin hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive the hormone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>repository corticotropin injection</intervention_name>
    <description>IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months</description>
    <arm_group_label>Adrenocorticotropin hormone</arm_group_label>
    <other_name>H.P. Acthar gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient diagnosed with MS according to McDonald criteria&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  Have a RR disease course&#xD;
&#xD;
          -  Have EDSS scores 0-5.5&#xD;
&#xD;
          -  Have a disease duration &lt;20 years&#xD;
&#xD;
          -  Sub-optimal response to Interferon beta-1a I.M. (Avonex®) while being on therapy for&#xD;
             at least 6 months defined as:&#xD;
&#xD;
          -  presence of a documented relapse within the last 12 months&#xD;
&#xD;
          -  or the presence of at least one enhancing T1 Gd lesion on an MRI performed within&#xD;
             previous 3 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Normal kidney functioning (creatinine clearance &gt;59)&#xD;
&#xD;
          -  None of the exclusion criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of relapse or steroid treatment within 60 days prior to study enrollment&#xD;
&#xD;
          -  Presence of neutralizing antibodies to IFNβ-1a I.M. prior to study enrollment&#xD;
&#xD;
          -  Presence of optic neuritis within less than 6 months prior to study enrollment&#xD;
&#xD;
          -  Diagnosis of osteoporosis (T score ≥2.5 SD)&#xD;
&#xD;
          -  Women who are pregnant, lactating or of childbearing age who do not consent to&#xD;
             approved contraceptive use during the study.&#xD;
&#xD;
          -  Abnormal blood tests, performed during the screening visit including: hepatitis B or&#xD;
             hepatitis C, ALT or AST greater than two times the upper limit of normal, abnormal&#xD;
             glucose fasting levels or already known diabetes&#xD;
&#xD;
          -  History of depression while on IFNβ-1a I.M.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zivadinov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Buffalo Neuroimaging Analysis Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bianca Weinstock-Guttman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacobs Neurological Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University at Buffalo, Buffalo General Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Robert Zivadinov, MD, PhD</investigator_full_name>
    <investigator_title>Director, Buffalo Neuroimaging Analysis Center, Professor</investigator_title>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>relapsing remitting</keyword>
  <keyword>RRMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

